BSE filing, NSE: WELSPUNLIV. Summary written from the filing by ALFA Finder's alert engine.
Welspun Living Ltd: key numbers
- Share price
- ₹215.51
- Market cap
- ₹20,671 Cr
- Revenue (annual)
- ₹9,399 Cr
- Net profit (annual)
- ₹204.4 Cr
- P/E (TTM)
- 74.5×Sector 49.0×
- Promoter holding
- 63.77%-2.59% QoQ
- FII holding
- 9.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welspun Living Ltd
All →Welspun Living Other Announcement
The company has filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI regulatory requirements.
Welspun Living Promoter Selling: ₹525.9 Cr
Welspun Living promoter, Welspun Group Master Trust, sold 2.45 crore shares worth ₹525.88 Crore via block deals on September 23, 2026.
- Value
- ₹525.9 Cr
- Promoter stake change
- -2.59%
Welspun Living Annual General Meeting
Welspun Living held its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements, dividend, and several special business items.
Welspun Living Promoter Selling
Welspun Group Master Trust disposed 2,44,71,102 shares (2.59%) of Welspun Living via block deal. Post-transaction promoter holding falls to 63.26%.
- Promoter stake change
- -2.59%
Welspun Living Credit Rating
India Ratings upgraded Welspun Global Brands (material subsidiary) bank loan rating to IN AA+/Stable from IN A1+. The ₹900 Crore facility upgrade strengthens the subsidiary's credit standing.
Welspun Living Other Announcement
Welspun Living Limited issued letters to shareholders with unregistered e-mails, providing a web-link to access the Notice of the 41st AGM and FY 2025-26 Annual Report.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.